

Lung dysfunction causes systemic hypoxia in estrogen receptor β knockout ($ER\beta^{-/-}$) mice

Andrea Morani*, Rodrigo P. A. Barros*[†], Otabek Imamov*, Kjell Hultenby[‡], Anders Arner[§], Margaret Warner*, and Jan-Åke Gustafsson*^{¶1}

*Department of Biosciences and Nutrition and [†]Clinical Research Centre, Karolinska Institute, Novum, S-141 86 Huddinge, Sweden; [‡]Department of Physiology and Biophysics, Institute of Biomedical Sciences, University of São Paulo, Av. Prof. Lineu Prestes, 1524, 05508-900, São Paulo, Brazil; and [§]Department of Physiology and Pharmacology, Karolinska Institute, Solna Campus, SE-171 77 Stockholm, Sweden

Contributed by Jan-Åke Gustafsson, March 17, 2006

Estrogen receptor β ($ER\beta$) is highly expressed in both type I and II pneumocytes as well as bronchiolar epithelial cells. $ER\alpha$ is not detectable in the adult lung. Lungs of adult female $ER\beta$ knockout ($ER\beta^{-/-}$) mice have already been reported to have fewer alveoli and reduced elastic recoil. In this article, we report that, by 5 months of age, there are large areas of unexpanded alveoli in lungs of both male and female $ER\beta^{-/-}$ mice. There is increased staining for collagen and, by EM, abnormal clusters of collagen fibers are seen in the alveolar septa of $ER\beta^{-/-}$ mice. Immunohistochemical analysis and Western blotting with lung membrane fractions of $ER\beta^{-/-}$ mice revealed down-regulation of caveolin-1, increased expression of membrane type-1 metalloproteinase, matrix metalloproteinase 2 (active form), and tissue inhibitors of metalloproteinases 2. Hypoxia, measured by immunohistochemical analysis for hypoxia-inducible factor 1 α and chemical adducts (with Hypoxyprobe), was evident in the heart, ventral prostate, periovarian sac, kidney, liver, and brain of $ER\beta^{-/-}$ mice under resting conditions. Furthermore, both male and female adult $ER\beta^{-/-}$ mice were reluctant to run on a treadmill and tissue hypoxia became very pronounced after exercise. We conclude that $ER\beta$ is necessary for the maintenance of the extracellular matrix composition in the lung and loss of $ER\beta$ leads to abnormal lung structure and systemic hypoxia. Systemic hypoxia may be responsible for the reported left and right heart ventricular hypertrophy and systemic hypertension in $ER\beta^{-/-}$ mice.

extracellular matrix | caveolin | metalloproteinase | hypertension | lung fibrosis

The importance of estrogens in development, physiology, and pathology of the lung has been known for some time. Estrogen hastens the onset of surfactant production and influences alveolar size and number. In fact, there is sexual dimorphism in late gestational and postnatal maturation of the lung in mammals (1, 2). The lack of detectable estrogen receptor α ($ER\alpha$) in the lung led to the belief that effects of estrogen on the lung were indirect. It was not until the discovery of $ER\beta$ in 1995 (3) that it became clear that estrogen, acting through $ER\beta$, has direct actions on the lung. $ER\beta$ knockout ($ER\beta^{-/-}$) mice (4) are characterized by right and left ventricle hypertrophy (5), systemic hypertension (6), ovarian dysfunction (7), and incompletely differentiated epithelium in ventral prostate (8), mammary gland (9), and colon (10). Compared with their WT littermates, female $ER\beta^{-/-}$ mice are reported to have fewer alveoli (11), reduced lung volume at a transpulmonary pressure of 20 cm of H_2O and reduced elastic recoil (12). Massaro *et al.* (12) attributed the lung phenotype to some defect of the extracellular matrix (ECM) composition. ECM is essential for normal tissue development, homeostasis, and wound repair. Physiologically, there is a balance between matrix protein accumulation and degradation. The ECM is composed of collagenous and non-collagenous proteins in which turnover is predominantly regulated by a family of enzymes called matrix metalloproteinases (MMPs). Recent data have revealed a major role for MMPs in

normal lung development and maintenance of lung architecture (13–17). Despite their key role in repair of the lung, MMPs can lead to destruction of alveolar epithelium, and overactivity of MMPs in the lung is thought to contribute to pulmonary diseases such as emphysema, idiopathic interstitial pneumonias, chronic obstructive pulmonary disease, and chronic reactive airway disease (18–21). MMPs are also involved in the invasion process of several metastatic cancer cells. The tissue inhibitors of metalloproteinases (TIMPs) are established endogenous inhibitors of MMPs. TIMP2 can bind to cell surface membrane type-1 metalloproteinase (MT1-MMP) to act as a “receptor” for pro-MMP2. The proteolytic modification of MMP2 from an inactive 72-kDa protein to a 62-kDa active form is catalyzed by MT1-MMP in association with TIMP2 (22).

MT1-MMP associates with caveolin-1 in lipid rafts on the cell surface. Expression of caveolin-1 does not affect the MT1-MMP-dependent activation of pro-MMP2, but there is evidence that caveolar localization of MT1-MMP inhibits MT1-MMP-dependent cell migration in several kinds of cancer (23). Caveolin-1 plays an essential role in caveolar formation (24). Lungs of caveolin-1 knockout mice are fibrotic with accumulation of ECM and fibroblast proliferation in the alveolar septa (25). Caveolin-1 is $ER\beta$ -regulated in skeletal muscle (26), and the lungs of caveolin-1 $^{-/-}$ mice bear some resemblance to lungs of $ER\beta^{-/-}$ mice.

In the present study, we investigated the pathological phenotype of the lung in $ER\beta^{-/-}$ mice. We report that, after 5 months of age, lungs of both male and female $ER\beta^{-/-}$ mice are fibrotic with large regions of unexpanded alveoli, down-regulation of caveolin-1, and increased expression of MT1-MMP, TIMP2, and the mature form of MMP2. Under resting conditions, there is hypoxia in many organs of $ER\beta^{-/-}$ mice, and this hypoxia becomes exaggerated when mice exercise on a treadmill. We suggest that lung dysfunction in $ER\beta^{-/-}$ mice induces systemic hypoxia, which can be involved in the heart hypertrophy (5) and systemic hypertension (6) observed in these mice.

Results

Phenotypic, Histological, and Immunohistochemical Examination of Lung Parenchyma in $ER\beta^{-/-}$ Mice. Hematoxylin/eosin-stained sections of lungs from 5-month-old WT mice look histologically normal (Fig. 1A). By 5 months of age (Fig. 1B), $ER\beta^{-/-}$ mouse lungs show large areas where alveoli are totally uninflated and septa are thickened. This age-related phenotype was evident to the same extent in both males and females but was not seen in WT littermates. Azan staining (Fig. 1C and D) indicates

Conflict of interest statement: In addition to the partial funding of this study from Karo Bio AB, J.-Å.G. is a cofounder, deputy board member, stockholder, and consultant of Karo Bio AB.

Abbreviations: ER, estrogen receptor α ; $ER\beta^{-/-}$, $ER\beta$ knockout; ECM, extracellular matrix; MMPs, matrix metalloproteinases; TIMPs, tissue inhibitors of metalloproteinases; MT1-MMP, membrane-type 1 metalloproteinase; HIF-1 α , hypoxia-inducible factor 1 α .

^{¶1}To whom correspondence should be addressed. E-mail: jan-ake.gustafsson@medn.ki.se.

© 2006 by The National Academy of Sciences of the USA




Fig. 1. Hematoxylin/eosin staining of lung from 1-year-old WT and $ER\beta^{-/-}$ mice. There is normal alveolar structure in WT lung sections (A), whereas areas of collapsed alveoli are evident in the $ER\beta^{-/-}$ lung sections (B). (C) Azan staining shows blue-stained collagenous extracellular material in the alveolar septa of WT lung section. (D) Intense blue-stained accumulation of ECM and thick alveolar septa in $ER\beta^{-/-}$ lung. (E) Immunoblotting of lung membrane fraction shows decreased ratio of inactive 72-kDa MMP2 form to the 62-kDa MMP2 active form and increased expression of MT1-MMP and TIMP2 in $ER\beta^{-/-}$ mice. (Magnification: A and B, $\times 10$; C and D, $\times 20$.)

substantial accumulation of collagen deposits in the alveolar septa of $ER\beta^{-/-}$ mice as confirmed in electron microscopic images (Fig. 2A–D). Immunofluorescence revealed that expression of caveolin-1 was much lower in the lungs of $ER\beta^{-/-}$ mice than in their WT littermates (Fig. 3A–B).




Fig. 2. EM of alveolar septa of WT and $ER\beta^{-/-}$ lung sections. Accumulation of collagen fibers are evident in $ER\beta^{-/-}$ lung septa (B and D) in longitudinal (arrows) and transversal (arrowheads) positions of the lung sections. In WT lung, collagen appears to be distributed in smaller and scattered fibers (A and C; arrows) than in $ER\beta^{-/-}$ lung.




Fig. 3. Immunofluorescence staining for caveolin-1 shows down-regulation of this protein in the lungs of $ER\beta^{-/-}$ mice (B) compared with WT mice (A). (Magnification: $\times 20$.)

Upon Western blotting with lung membrane fractions, two specific bands were detected with antibodies specific for MMP2. The 72-kDa band represents the inactive MMP2 and the 62-kDa band represents the proteolytically cleaved, active MMP2. Compared with WT littermates, in $ER\beta^{-/-}$ mice the ratio of the two bands is changed in favor of the smaller active protein (Fig. 1E). There are also increased levels of MT1-MMP, the protease involved in cleavage of MMP2, and TIMP2.

Hypoxic Organs in $ER\beta^{-/-}$ Mice. As represented in Fig. 4A–F, expression of the hypoxia-inducible factor 1 α (HIF-1 α) in cardiomyocytes, epithelial cells of ventral prostate, and the ovararian sac is higher in $ER\beta^{-/-}$ mice than in WT littermates.

Hydroxyprobe is an exogenous nitroaromatic compound




Fig. 4. Immunohistochemical detection of HIF-1 α in heart, ventral prostate, and ovararian sac. There is no nuclear staining in the cardiomyocytes of WT mice (A). Several cells are positively stained in the nucleus in the heart section of $ER\beta^{-/-}$ mice (B). Very few weakly stained epithelial cell nuclei are found in the ventral prostate of WT mice (C), whereas almost the whole prostatic epithelium of $ER\beta^{-/-}$ mice is intensively stained (D). There are very strong positive signals in many cells of the periovarian sac in the $ER\beta^{-/-}$ mice (F) but only weakly stained cells in WT sections (E). There were no HIF-1 α -positive cells in the ovary of either WT or $ER\beta^{-/-}$ mice. (Magnification: A–D, $\times 20$; E and F, $\times 40$.)




Fig. 7. Immunohistochemical detection of Hypoxyprobe chemical adducts in mice killed after physical strain on a treadmill (speed, 10 m/min). (A) A weak cytoplasmic signal is evident in the hepatocytes close to the central vein (CV) in WT mice. PV, portal veins. (B) Extended regions of strong cytoplasmic and nuclear staining in the liver of $ER\beta^{-/-}$ mice. (C) Some tubular epithelial cells are stained in both cytoplasm and nucleus of WT kidney, whereas most cells show only cytoplasmic signal. (D) Almost the entire epithelial tubular cell of the kidney of $ER\beta^{-/-}$ mice shows strong positive signals in both cytoplasm and nucleus. (E) There are very few stained neurons in brain section of WT mice. (F) There are many areas with stained neurons in the section of $ER\beta^{-/-}$ mice. (Magnification: A and B, $\times 10$; C–F, $\times 20$; Inset, $\times 40$.)

MT1-MMP from the lipid rafts of the plasma membrane, and this can interfere with several of the enzymatic activities of MT1-MMP (21). We speculate that $ER\beta$ regulates both the expression of MT1-MMP and its localization on the lipid rafts of the plasma membrane. Physiologically, there is a balance between deposition and degradation of the ECM and disruption of this balance leads to lung-fibrotic diseases or impaired wound-healing (34). MMP activities are responsible for maintenance of ECM.

Immunohistochemical analysis of HIF-1 α and Hypoxyprobe chemical adducts revealed several hypoxic organs in $ER\beta$ knockout mice (Fig. 5). In our experimental setting, 1-year-old $ER\beta^{-/-}$ mice were much less tolerant to physical strain on a treadmill than were WT littermates: $ER\beta$ -deficient mice “refused” to run for >5 min, whereas WT mice could continue to run up to 10–15 min. Hypoxyprobe staining shows that (Fig. 6), after exercise, hypoxia in liver, kidney, and brain was much more severe in the $ER\beta^{-/-}$ than WT mice. The intolerance of $ER\beta^{-/-}$ mice to physical exercise may be due to systemic hypoxia caused by lung dysfunction.

In conclusion, $ER\beta^{-/-}$ mice have abnormal alveolar structure, abnormal ECM composition, and dysregulation of MMP2, MT1-MMP, TIMP2, and caveolin-1. The chronic hypoxia of $ER\beta^{-/-}$ mice must be considered as a contributing factor in other abnormalities in these mice, including hypertension that develops in both male and female $ER\beta^{-/-}$ mice after 6 months of age (6). Systemic hypertension is associated with peripheral vaso-

constriction, which can be caused by several factors, including adaptations to chronic hypoxia (35, 36). The creation of tissue-specific knockout mice may be very useful to study the role of $ER\beta$ in the cardiovascular system and other tissues, avoiding the secondary effects due to systemic hypoxia.

Materials and Methods

Animals. $ER\beta^{-/-}$ mice were from our colony (4). Mice were housed in the Karolinska University Hospital Animal Facility (Huddinge, Sweden) in a controlled environment on a 12-h light/dark illumination schedule and fed a standard pellet diet with water provided ad libitum. Mice were killed by cervical dislocation and exsanguinated by cutting of the abdominal aorta. For immunohistochemical studies, lungs were fixed in 4% paraformaldehyde and embedded in paraffin; for Western blotting, lungs were frozen in liquid nitrogen.

Physical Strain Test. One group of 1-year-old male and female $ER\beta^{-/-}$ mice and another group of male and female WT mice of the same age were subjected to physical exercise on a treadmill set at the speed of 10 m/min.

Western Blotting. The lung membrane fractions of $ER\beta^{-/-}$ and WT mice were analyzed by Western blotting with antibodies raised against MMP2, MT1-MMP, and TIMP-2. Frozen tissues were homogenized for 1 min each with a polytron in 25 ml of PBS buffer containing a protease inhibitor mixture according to manufacturer’s instructions (Roche Diagnostics). The homogenate was centrifuged for 10 min at 1,000 rpm (rotor JA-17; Beckman). The pellet contained nuclear protein, and the supernatant contained mitochondrial, cytosolic, and membrane proteins. Mitochondrial proteins were precipitated and removed by centrifugation of the supernatant at 9,000 rpm for 20 min (rotor JA-17). After ultracentrifugation at 30,000 rpm for 60 min (rotor Ti50; Beckman), membrane proteins were precipitated and resuspended in PBS. The membrane proteins of WT and $ER\beta^{-/-}$ mice lung were dissolved in SDS sample buffer and resolved on 4–20% gradient SDS/polyacrylamide gels (Invitrogen) in Tris-glycine buffer. The protein contents of the lanes were compared by Coomassie blue staining of the gel. The same amount of proteins were loaded on another gel and then transferred to poly(vinylidene difluoride) membranes (Amersham Pharmacia Biosciences) by electroblotting in Tris-glycine buffer. Molecular weight markers were Precision Plus protein standards (Bio-Rad). The membrane was then incubated in blocking solution containing 5% fat-free milk and 0.1% Nonidet P-40 in PBS for 1 h at room temperature. Incubations with mouse anti-MMP2, mouse anti-MT1-MMP, or rabbit anti-TIMP2 antibodies were performed in blocking solution overnight at 4°C. After washing, secondary peroxidase-conjugated goat anti-mouse or anti-rabbit antibodies (1:3,000; Sigma) were applied in blocking solution for 1 h at room temperature. After washing, detection with an enhanced chemiluminescence ECL kit (Amersham Pharmacia) was performed.

EM. Lungs were dissected, and small pieces were cut and immediately fixed in 2% glutaraldehyde/0.5% paraformaldehyde in 0.1 M sodium cacodylate buffer (caco)/0.1 M sucrose/3 mM $CaCl_2$ (pH 7.4) overnight. Specimens were rinsed in 0.15 M caco and postfixed by incubation for 2 h in 2% osmium tetroxide in 0.07 M caco containing 3 mM $CaCl_2$. The specimens were dehydrated in an ascending series of alcohol into acetone and embedded in LX-112 epoxy resin (Ladd Research Industries, Burlington, VT). Semithin sections (0.5 μ m) were placed on glass slides, stained with toluidine blue, and examined in a light microscope. Ultrathin sections were cut and contrasted with uranyl acetate followed by lead citrate and examined in a Tecnai 10 (FEI, Eindhoven, The Netherlands) transmission electron microscope set at 80 kV.

Tissue Hypoxia Detection by a Hypoxyprobe Kit. Hypoxyprobe solution was injected 60 mg/kg i.p. 15 min before the running test. The animals were killed just after the physical strain. For the mice not exposed to physical exercise, the Hypoxyprobe treatment was done 60 min before death.

Immunohistochemistry. Representative blocks of paraffin-embedded tissues were cut at a 4- μ m thickness, dewaxed, and rehydrated. For all of the stainings, the antigens were retrieved by boiling in 10 mM citrate buffer (pH 7.0) for 20 min. In the case of HIF-1 α and Hypoxyprobe stainings, the sections were incubated in 0.5% H₂O₂ in PBS for 30 min at room temperature to quench endogenous peroxidase and then incubated in 0.5% Triton X-100 in PBS for 30 min. To block the nonspecific binding, sections were incubated in 1% BSA plus 0.1% Nonidet P-40 in PBS for 1 h at 4°C. Sections were incubated with mouse anti-HIF-1 α or mouse anti-Hypoxyprobe antibodies, both at a dilution of 1:50 in 1% BSA and 0.1% Nonidet P-40 in PBS overnight at 4°C. After washing, sections were incubated with the secondary antibodies (biotinylated goat IgG anti-mouse for HIF-1 α and biotinylated goat IgG F(ab')₂ anti-mouse for Hypoxyprobe) for 1 h at room temperature. The Vectastain ABC kit (Vector Laboratories) was used for the avidin-biotin complex (ABC) method according to the manufacturer's instructions. Peroxidase activity was visualized with 3,3'-diaminobenzidine (DAKO). The sections were lightly counterstained with

hematoxylin or DAPI, dehydrated through an ethanol series to xylene, and mounted. For caveolin-1 staining, the sections were incubated with rabbit anti-caveolin-1 in 3% BSA plus 0.1% Nonidet P-40 in PBS overnight at 4°C. After washing, sections were incubated with goat Cy3 anti-rabbit antibody. The sections were then dehydrated and directly mounted in Vectashield antifading medium (Vector Laboratories). The visualizations were done by using a light microscope or Zeiss fluorescence microscope with filters suitable for selectively detecting the fluorescence of Cy3 (red).

Chemicals and Antibodies. We purchased DAPI from Sigma-Aldrich and the Hypoxyprobe Kit from Chemicon International (Temecula, CA). The following antibodies were used: mouse monoclonal anti-HIF-1 α from Chemicon International, mouse monoclonal anti-MMP2 from Zymed, mouse monoclonal anti-MT1-MMP from Chemicon International, rabbit polyclonal anti-TIMP2 from Abcam, Inc. (Cambridge, MA), rabbit polyclonal anti-caveolin-1 from BD Biosciences, Cy3 anti-rabbit from Jackson ImmunoResearch, and biotinylated goat IgG anti-mouse and biotinylated goat F(ab')₂ IgG from Zymed.

We thank Annemarie Witte and José Inzunza for excellent technical assistance and animal management. This work was supported by the European Commission funded CASCADE Network of Excellence (FOOD-CT-2004-506319), the Swedish Cancer Fund, and Karo Bio AB (Huddinge, Sweden).

- Ballard, P. L. (1989) *Endocr. Rev.* **10**, 165–181.
- Mendelson, C. R. & Boggaram, V. (1990) *Baillieres Clin. Endocrinol. Metab.* **4**, 351–378.
- Kuiper, G. G., Enmark, E., Pelto-Huikko, M., Nilsson, S. & Gustafsson, J. A. (1996) *Proc. Natl. Acad. Sci. USA* **93**, 5925–5930.
- Krege, J. H., Hodgin, J. B., Couse, J. F., Enmark, E., Warner, M., Mahler, J. F., Sar, M., Korach, K. S., Gustafsson, J. A. & Smithies, O. (1998) *Proc. Natl. Acad. Sci. USA* **95**, 15677–15682.
- Forster, C., Kietz, S., Hultenby, K., Warner, M. & Gustafsson, J. A. (2004) *Proc. Natl. Acad. Sci. USA* **101**, 14234–14239.
- Zhu, Y., Bian, Z., Lu, P., Karas, R. H., Bao, L., Cox, D., Hodgins, J., Shaul, P. W., Thoren, P., Smithies, O., et al. (2002) *Science* **295**, 505–508.
- Cheng, G., Weihua, Z., Makinen, S., Makela, S., Saji, S., Warner, M., Gustafsson, J. A. & Hovatta, O. (2002) *Biol. Reprod.* **66**, 77–84.
- Imamov, O., Morani, A., Shim, G. J., Omoto, Y., Thulin-Andersson, C., Warner, M. & Gustafsson, J. A. (2004) *Proc. Natl. Acad. Sci. USA* **101**, 9375–9380.
- Forster, C., Makela, S., Warri, A., Kietz, S., Becker, D., Hultenby, K., Warner, M. & Gustafsson, J. A. (2002) *Proc. Natl. Acad. Sci. USA* **99**, 15578–15583.
- Wada-Hiraike, O., Imamov, O., Hiraike, H., Hultenby, K., Schwend, T., Omoto, Y., Warner, M. & Gustafsson, J. A. (2006) *Proc. Natl. Acad. Sci. USA* **103**, 2959–2964.
- Patrone, C., Cassel, T. N., Pettersson, K., Piao, Y. S., Cheng, G., Ciana, P., Maggi, A., Warner, M., Gustafsson, J. A. & Nord, M. (2003) *Mol. Cell. Biol.* **23**, 8542–8552.
- Massaro, D. & Massaro, G. D. (2004) *Am. J. Physiol.* **287**, L1154–L1159.
- Arden, M. G., Spearman, M. A. & Adamson, I. Y. (1993) *Am. J. Respir. Cell Mol. Biol.* **9**, 99–105.
- Reponen, P., Sahlberg, C., Huhtala, P., Hurskainen, T., Thesleff, I. & Tryggvason, K. (1992) *J. Biol. Chem.* **267**, 7856–7862.
- Fukuda, Y., Ishizaki, M., Okada, Y., Seiki, M. & Yamanaka, N. (2000) *Am. J. Physiol.* **279**, L555–L561.
- Atkinson, J. J., Holmbeck, K., Yamada, S., Birkedal-Hansen, H., Parks, W. C. & Senior, R. M. (2005) *Dev. Dyn.* **232**, 1079–1090.
- Masumoto, K., de Rooij, J. D., Suita, S., Rottier, R., Tibboel, D. & de Krijger, R. R. (2005) *Histopathology* **47**, 410–419.
- Parks, W. C. & Shapiro, S. D. (2001) *Respir. Res.* **2**, 10–19.
- Elkington, P. T. & Friedland, J. S. (2006) *Thorax* **61**, 259–266.
- Corbel, M., Belleguic, C., Boichot, E. & Lagente, V. (2002) *Cell Biol. Toxicol.* **18**, 51–61.
- Henry, M. T., McMahon, K., Mackarel, A. J., Prikk, K., Sorsa, T., Maisi, P., Sepper, R., Fitzgerald, M. X. & O'Connor, C. M. (2002) *Eur. Respir. J.* **20**, 1220–1227.
- Butler, G. S., Butler, M. J., Atkinson, S. J., Will, H., Tamura, T., van Westrum, S. S., Crabbe, T., Clements, J., d'Ortho, M. P. & Murphy, G. (1998) *J. Biol. Chem.* **273**, 871–880.
- Annabi, B., Lachambre, M., Bousquet-Gagnon, N., Page, M., Gingras, D. & Beliveau, R. (2001) *Biochem. J.* **353**, 547–553.
- Rothberg, K. G., Heuser, J. E., Donzell, W. C., Ying, Y. S., Glenney, J. R. & Anderson, R. G. (1992) *Cell* **68**, 673–682.
- Drab, M., Verkade, P., Elger, M., Kasper, M., Lohn, M., Lauterbach, B., Menne, J., Lindschau, C., Mende, F., Luft, F. C., et al. (2001) *Science* **293**, 2449–2452.
- Barros, R. P., Machado, U. F., Warner, M. & Gustafsson, J. A. (2006) *Proc. Natl. Acad. Sci. USA* **103**, 1605–1608.
- Cline, J. M., Thrall, D. E., Page, R. L., Franko, A. J. & Raleigh, J. A. (1990) *Br. J. Cancer* **62**, 925–931.
- Raleigh, J. A., Calkins-Adams, D. P., Rinker, L. H., Ballenger, C. A., Weissler, M. C., Fowler, W. C., Jr., Novotny, D. B. & Varia, M. A. (1998) *Cancer Res.* **58**, 3765–3768.
- Hodgkiss, R. J. (1998) *Anticancer Drug Des.* **13**, 687–702.
- Kennedy, A. S., Raleigh, J. A., Perez, G. M., Calkins, D. P., Thrall, D. E., Novotny, D. B. & Varia, M. A. (1997) *Int. J. Radiat. Oncol. Biol. Phys.* **37**, 897–905.
- Samoszuk, M. K., Walter, J. & Mechtner, E. (2004) *J. Histochem. Cytochem.* **52**, 837–839.
- Oblander, S. A., Zhou, Z., Galvez, B. G., Starcher, B., Shannon, J. M., Durbeej, M., Arroyo, A. G., Tryggvason, K. & Apte, S. S. (2005) *Dev. Biol.* **277**, 255–269.
- Chakrabarti, S. & Patel, K. D. (2005) *Exp. Lung Res.* **31**, 599–621.
- Razzaque, M. S. & Taguchi, T. (2003) *Pathol. Int.* **53**, 133–145.
- Vaziri, N. D. & Wang, Z. Q. (1996) *Kidney Int.* **49**, 1457–1463.
- Calbet, J. A. (2003) *J. Physiol.* **551**, 379–386.